Head-to-head review of nicotinamide mononucleotide and nicotinamide riboside — pharmacokinetics, NAD+ uplift, human trial endpoints, and dosing strategy.
Nicotinamide adenine dinucleotide (NAD+) declines roughly 50% between ages 20 and 60 in most tissues, with measurable losses in skeletal muscle, brain, and skin. Two oral precursors dominate the supplement market: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Both raise circulating NAD+. The interesting question is whether either translates into clinically meaningful endpoints — and which one is the better default choice in 2026.
NAD+ is the obligate cofactor for three enzyme families that govern aging biology:
When NAD+ falls, sirtuin output falls with it. Mitochondrial quality control suffers. The PARP–CD38 tax on the remaining pool grows.
NR is converted to NAD+ via the salvage pathway through NMN as an intermediate. NMN can also be dephosphorylated to NR for cellular uptake via the Slc12a8 transporter, although the importance of that transporter in humans is debated. The net result: both molecules end up feeding the same NAD+ pool, but the path length and tissue targeting differ slightly.
In human pharmacokinetic studies, oral NR raises whole-blood NAD+ by 40–90% at 300–1,000 mg per day. NMN trials report 11–38% increases at 250–500 mg per day, with sublingual delivery producing the largest acute peaks.
| Trial | Compound | Dose | Population | Primary finding | |------|----------|------|------------|----------------| | Yoshino 2021 | NMN | 250 mg/day | Prediabetic women | +25% muscle insulin sensitivity | | Martens 2018 | NR | 1,000 mg/day | Healthy older adults | Lowered SBP in stage 1 hypertension | | Igarashi 2022 | NMN | 250 mg/day | Older adults | Improved gait speed and grip strength | | Dollerup 2018 | NR | 2,000 mg/day | Obese men | Well tolerated; modest metabolic change |
The pattern is consistent: both compounds elevate NAD+, and the functional benefits cluster around metabolic flexibility, exercise capacity, and mild cardiovascular signal. No trial yet has reported a hard longevity endpoint.
For a healthy adult under 50 with no metabolic disease, the choice between NMN and NR is closer to a coin flip than the supplement industry suggests. Pick the formulation you can dose consistently:
Either way, the modifiable lever with the biggest NAD+ effect remains zone 2 cardiovascular training combined with caloric restraint. A supplement is an accelerant, not a substitute.
Both reliably raise whole-blood NAD+ in human trials. NMN has slightly stronger functional endpoint data in older adults (gait speed, insulin sensitivity), while NR has the longest safety record. The differences are modest at equivalent NAD+ exposure.
Most human trials use 250–600 mg of either compound daily. There is no convincing evidence for benefit beyond ~1 g per day in healthy adults.
No. Long-term human safety data through 12 months at 300 mg/day is reassuring for NR. NMN has shorter long-term data but a similar metabolic profile.
Methyl-group depletion from NAD+ precursor metabolism is theoretical. Adding 500 mg–1 g of trimethylglycine is a low-cost hedge, especially if dietary choline and B-vitamins are inadequate.
Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.
One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.